News | Stent Grafts | February 14, 2019

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028

Abdominal aortic stent grafts will remain largest segment due to greater prevalence of abdominal aortic aneurysms

Aortic Stent Graft Global Market to Reach $5.4 Billion by 2028

February 14, 2019 — Abdominal aortic stent grafts will remain the largest segment in the global aortic stent graft market at least through 2028 due to the high prevalence of abdominal aortic aneurysms (AAA) relative to thoracic abdominal aneurysms (TAA), according to a new report from GlobalData. The abdominal segment will reach an estimated $2.8 billion global value by 2028, while the overall global aortic stent graft market is expected to reach $4.5 billion in the same period. This represents a compound annual growth rate of 5.4 percent between 2018 and 2028.

The company’s latest report, ‘Aortic Stent Grafts – Cardiovascular Market Analysis and Forecast Model’ reveals that Asia Pacific will be one of the fastest growing regions at a CAGR of 6.7 percent during the forecast period, with North America and Europe following closely behind at 4.9 percent and 4.6 percent, respectively.

David Brown, medical devices analyst at GlobalData commented, “Advances in stent graft design, such as with fenestrated and branched endografts, continue to expand the eligible patient pool for endovascular repair by addressing increasingly complex aneurysm anatomies.”

Although endovascular repair of aneurysms is a commonly used procedure and is increasingly employed over open repair procedures for the majority of aneurysms, barriers to market growth include the high cost of aortic stent graft devices and the relative lack of long-term outcome benefits versus open aortic repair.

For more information: www.globaldata.com

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...